Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
Lineage Commitment01:21

Lineage Commitment

Commitment is the  process whereby stem cells:
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Space-associated stem cell hallmarks of aging and resilience in astronauts.

Cell stem cell·2025
Same author

Nanobioreactor detection of space-associated hematopoietic stem and progenitor cell aging.

Cell stem cell·2025
Same author

Biomanufacturing in low Earth orbit: A paradigm shift.

Stem cell reports·2025
Same author

3D insights: JAK2 46/1 haplotype shapes MPN development.

Blood·2025
Same author

The Potential of JAG Ligands as Therapeutic Targets and Predictive Biomarkers in Multiple Myeloma.

International journal of molecular sciences·2023
Same author

Stem-Cell Aging and Pathways to Precancer Evolution.

The New England journal of medicine·2023
Same journal

Cytarabine-based induction and oral maintenance therapy for a single system with single-site Langerhans cell histiocytosis.

International journal of hematology·2026
Same journal

Long-term treatment-free remission in CML after early dasatinib discontinuation due to interstitial pneumonitis.

International journal of hematology·2026
Same journal

Correction to: Low reticulocyte count at infusion is a risk factor for high-grade cytokine release syndrome in chimeric antigen receptor T cell therapy.

International journal of hematology·2026
Same journal

The efficacy of prophylactic tranexamic acid in patients with hematologic malignancy: a systematic review and meta-analysis.

International journal of hematology·2026
Same journal

Current status and challenges of TCR-T cell therapy for AML/MDS.

International journal of hematology·2026
Same journal

Efficacy and safety of maribavir in Japanese patients with post-transplant cytomegalovirus infections: a phase III study.

International journal of hematology·2026
See all related articles

Related Experiment Video

Updated: Jun 12, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Molecular pathways to CML stem cells.

Kristen N Rice1, Catriona H M Jamieson

  • 1Moores UCSD Cancer Center, University of California, 3855 Health Sciences Drive, Mail Code 0820, La Jolla, CA 92093-0820, USA.

International Journal of Hematology
|June 10, 2010
PubMed
Summary
This summary is machine-generated.

Imatinib is effective for chronic myeloid leukemia (CML) but does not cure it. Leukemic stem cells (LSC) persist, causing relapse, and understanding their pathways is key for new CML therapies.

More Related Videos

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Related Experiment Videos

Last Updated: Jun 12, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Area of Science:

  • Hematology
  • Oncology
  • Stem Cell Biology

Background:

  • Imatinib revolutionized chronic myeloid leukemia (CML) treatment but fails to cure the disease in many patients.
  • Resistance, intolerance, and relapse are common issues, especially in advanced CML, often linked to persistent leukemic stem cells (LSC).
  • Leukemic stem cells (LSC) are a small, quiescent population responsible for disease initiation and maintenance, evading current therapies.

Purpose of the Study:

  • To review the molecular pathways driving the generation and survival of CML stem cells.
  • To discuss the implications of these pathways for developing novel CML therapeutic strategies.
  • To understand why imatinib therapy does not eradicate CML and leads to relapse.

Main Methods:

  • Literature review of studies identifying deregulated molecular pathways in CML stem cells.
  • Analysis of evidence regarding the role of leukemic stem cells in CML pathogenesis and treatment resistance.
  • Synthesis of findings to discuss therapeutic implications.

Main Results:

  • Imatinib does not eradicate CML stem cells (LSC), which are responsible for disease persistence and relapse.
  • LSC possess unique properties, including quiescence and evasion of apoptosis and immunity, similar to normal hematopoietic stem cells.
  • Deregulated molecular pathways are critical for LSC generation and survival.

Conclusions:

  • Targeting leukemic stem cells (LSC) is essential for achieving a cure in chronic myeloid leukemia (CML).
  • Understanding the molecular pathways governing LSC is crucial for developing more effective CML therapies beyond current tyrosine kinase inhibitors.
  • Future CML treatments must focus on eradicating the LSC population to prevent relapse and achieve long-term remission.